A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial
Purpose: DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous insertion/deletion mutations at microsatellites. Mutations of coding microsatellites (cMS) lead to the generation of immunogenic fr...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2020
|
| In: |
Clinical cancer research
Year: 2020, Volume: 26, Issue: 17, Pages: 4503-4510 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-19-3517 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-19-3517 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/26/17/4503 
|
| Author Notes: | Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1741931029 | ||
| 003 | DE-627 | ||
| 005 | 20220819042918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201203s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-19-3517 |2 doi | |
| 035 | |a (DE-627)1741931029 | ||
| 035 | |a (DE-599)KXP1741931029 | ||
| 035 | |a (OCoLC)1341382924 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kloor, Matthias |d 1972- |e VerfasserIn |0 (DE-588)124552803 |0 (DE-627)363416609 |0 (DE-576)294228616 |4 aut | |
| 245 | 1 | 2 | |a A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers |b a phase I/IIa clinical trial |c Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz |
| 264 | 1 | |c September 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.12.2020 | ||
| 520 | |a Purpose: DNA mismatch repair (MMR) deficiency is a hallmark of Lynch syndrome, the most common inherited cancer syndrome. MMR-deficient cancer cells accumulate numerous insertion/deletion mutations at microsatellites. Mutations of coding microsatellites (cMS) lead to the generation of immunogenic frameshift peptide (FSP) neoantigens. As the evolution of MMR-deficient cancers is triggered by mutations inactivating defined cMS-containing tumor suppressor genes, distinct FSP neoantigens are shared by most MMR-deficient cancers. To evaluate safety and immunogenicity of an FSP-based vaccine, we performed a clinical phase I/IIa trial (Micoryx). - Patients and Methods: The trial comprised three cycles of four subcutaneous vaccinations (FSP neoantigens derived from mutant AIM2, HT001, TAF1B genes) mixed with Montanide ISA-51 VG over 6 months. Inclusion criteria were history of MMR-deficient colorectal cancer (UICC stage III or IV) and completion of chemotherapy. Phase I evaluated safety and toxicity as primary endpoint (six patients), phase IIa addressed cellular and humoral immune responses (16 patients). - Results: Vaccine-induced humoral and cellular immune responses were observed in all patients vaccinated per protocol. Three patients developed grade 2 local injection site reactions. No vaccination-induced severe adverse events occurred. One heavily pretreated patient with bulky metastases showed stable disease and stable CEA levels over 7 months. - Conclusions: FSP neoantigen vaccination is systemically well tolerated and consistently induces humoral and cellular immune responses, thus representing a promising novel approach for treatment and even prevention of MMR-deficient cancer. | ||
| 700 | 1 | |a Reuschenbach, Miriam |d 1980- |e VerfasserIn |0 (DE-588)13879734X |0 (DE-627)703109723 |0 (DE-576)309094054 |4 aut | |
| 700 | 1 | |a Pauligk, Claudia |d 1973- |e VerfasserIn |0 (DE-588)124633498 |0 (DE-627)363458352 |0 (DE-576)294422609 |4 aut | |
| 700 | 1 | |a Heider, Julia |d 1976- |e VerfasserIn |0 (DE-588)125007795 |0 (DE-627)370703162 |0 (DE-576)294615741 |4 aut | |
| 700 | 1 | |a Rafiyan, Mohammad-Reza |e VerfasserIn |4 aut | |
| 700 | 1 | |a Batran, Salah-Eddin al- |e VerfasserIn |0 (DE-588)114597359 |0 (DE-627)626875730 |0 (DE-576)323432840 |4 aut | |
| 700 | 1 | |a Tariverdian, Mirjam |d 1947- |e VerfasserIn |0 (DE-588)131506641 |0 (DE-627)510155995 |0 (DE-576)298552000 |4 aut | |
| 700 | 1 | |a Jäger, Elke |e VerfasserIn |0 (DE-588)137143192 |0 (DE-627)589744321 |0 (DE-576)302371052 |4 aut | |
| 700 | 1 | |a Knebel Doeberitz, Magnus von |e VerfasserIn |0 (DE-588)1022165291 |0 (DE-627)71693289X |0 (DE-576)364934239 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 26(2020), 17, Seite 4503-4510 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers a phase I/IIa clinical trial |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:17 |g pages:4503-4510 |g extent:8 |a A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers a phase I/IIa clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-19-3517 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/26/17/4503 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250109 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1022165291 |a Knebel Doeberitz, Magnus von |m 1022165291:Knebel Doeberitz, Magnus von |d 910000 |d 912000 |d 50000 |e 910000PK1022165291 |e 912000PK1022165291 |e 50000PK1022165291 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 9 |y j | ||
| 998 | |g 131506641 |a Tariverdian, Mirjam |m 131506641:Tariverdian, Mirjam |d 910000 |d 910100 |e 910000PT131506641 |e 910100PT131506641 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 998 | |g 13879734X |a Reuschenbach, Miriam |m 13879734X:Reuschenbach, Miriam |d 910000 |d 912000 |d 50000 |e 910000PR13879734X |e 912000PR13879734X |e 50000PR13879734X |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 2 | ||
| 998 | |g 124552803 |a Kloor, Matthias |m 124552803:Kloor, Matthias |d 910000 |d 912000 |d 50000 |e 910000PK124552803 |e 912000PK124552803 |e 50000PK124552803 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1741931029 |e 3816676340 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 03.12.2020"],"id":{"doi":["10.1158/1078-0432.CCR-19-3517"],"eki":["1741931029"]},"title":[{"title_sort":"frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers","title":"A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers","subtitle":"a phase I/IIa clinical trial"}],"recId":"1741931029","language":["eng"],"origin":[{"dateIssuedDisp":"September 2020","dateIssuedKey":"2020"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"relHost":[{"disp":"A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers a phase I/IIa clinical trialClinical cancer research","note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"id":{"issn":["1557-3265"],"eki":["325489971"],"zdb":["2036787-9"]},"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"part":{"pages":"4503-4510","year":"2020","extent":"8","volume":"26","issue":"17","text":"26(2020), 17, Seite 4503-4510"},"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Association for Cancer Research"]},"language":["eng"],"origin":[{"dateIssuedKey":"1995","publisherPlace":"Philadelphia, Pa. [u.a.]","dateIssuedDisp":"1995-","publisher":"AACR"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"American Association for Cancer Research"}],"pubHistory":["1.1995 -"],"recId":"325489971"}],"person":[{"family":"Kloor","roleDisplay":"VerfasserIn","given":"Matthias","display":"Kloor, Matthias","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Reuschenbach","given":"Miriam","role":"aut","display":"Reuschenbach, Miriam"},{"display":"Pauligk, Claudia","role":"aut","given":"Claudia","family":"Pauligk","roleDisplay":"VerfasserIn"},{"display":"Heider, Julia","role":"aut","given":"Julia","family":"Heider","roleDisplay":"VerfasserIn"},{"family":"Rafiyan","roleDisplay":"VerfasserIn","display":"Rafiyan, Mohammad-Reza","role":"aut","given":"Mohammad-Reza"},{"display":"Batran, Salah-Eddin al-","role":"aut","given":"Salah-Eddin al-","family":"Batran","roleDisplay":"VerfasserIn"},{"family":"Tariverdian","roleDisplay":"VerfasserIn","display":"Tariverdian, Mirjam","role":"aut","given":"Mirjam"},{"roleDisplay":"VerfasserIn","family":"Jäger","display":"Jäger, Elke","role":"aut","given":"Elke"},{"display":"Knebel Doeberitz, Magnus von","role":"aut","given":"Magnus von","roleDisplay":"VerfasserIn","family":"Knebel Doeberitz"}],"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad-Reza Rafiyan, Salah-Eddin Al-Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz"]}} | ||
| SRT | |a KLOORMATTHFRAMESHIFT2020 | ||